Callan Family Office LLC Purchases Shares of 2,246 United Therapeutics Corporation $UTHR

Key Points

• Callan Family Office acquired 2,246 United Therapeutics shares worth approximately $1.2 million, while institutional investors collectively own 94.08% of the company.
• United Therapeutics insiders sold 434,075 shares valued at roughly $233.9 million over the past three months, including sales by the CEO and an executive vice president.
• Analysts maintain a generally positive outlook, with 11 Buy ratings and two Holds, producing a consensus “Moderate Buy” rating and an average price target of $646 versus the stock’s $512.88 opening price.

Callan Family Office LLC acquired a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,246 shares of the biotechnology company's stock, valued at approximately $1,217,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. BlackRock Inc. acquired a new stake in shares of United Therapeutics in the 2nd quarter valued at about $2,868,735,000. Avoro Capital Advisors LLC raised its stake in United Therapeutics by 17.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company's stock worth $1,269,803,000 after buying an additional 383,838 shares during the period. Wellington Management Group LLP raised its stake in United Therapeutics by 74.5% during the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company's stock worth $1,189,617,000 after buying an additional 1,042,711 shares during the period. AQR Capital Management LLC boosted its holdings in United Therapeutics by 29.9% in the fourth quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company's stock worth $624,508,000 after acquiring an additional 295,221 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its holdings in United Therapeutics by 8.9% in the first quarter. Janus Henderson Group PLC now owns 866,930 shares of the biotechnology company's stock worth $514,016,000 after acquiring an additional 70,829 shares in the last quarter. Institutional investors own 94.08% of the company's stock.

Insiders Place Their Bets

In other United Therapeutics news, EVP Paul A. Mahon sold 8,300 shares of United Therapeutics stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $523.14, for a total transaction of $4,342,062.00. Following the transaction, the executive vice president directly owned 45,172 shares of the company's stock, valued at $23,631,280.08. The trade was a 15.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of the company's stock in a transaction on Friday, August 21st. The stock was sold at an average price of $518.39, for a total transaction of $4,924,705.00. Following the completion of the sale, the chief executive officer owned 324,443 shares of the company's stock, valued at approximately $168,188,006.77. The trade was a 2.84% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 434,075 shares of company stock valued at $233,942,595 over the last three months. 8.60% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research firms have recently commented on UTHR. Morgan Stanley set a $515.00 price objective on United Therapeutics in a report on Thursday, August 6th. Royal Bank Of Canada cut their target price on United Therapeutics from $704.00 to $677.00 and set an "outperform" rating on the stock in a report on Thursday, August 6th. Bank of America reduced their price target on shares of United Therapeutics from $620.00 to $613.00 and set a "neutral" rating for the company in a research report on Friday, July 10th. TD Cowen restated a "buy" rating on shares of United Therapeutics in a research note on Thursday, May 21st. Finally, Wells Fargo & Company upgraded shares of United Therapeutics from an "equal weight" rating to an "overweight" rating and boosted their price target for the company from $575.00 to $735.00 in a research note on Thursday, May 7th. Eleven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, United Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $646.00.

United Therapeutics Stock Performance

Shares of UTHR opened at $512.88 on Tuesday. The stock has a 50 day moving average price of $532.35 and a two-hundred day moving average price of $538.04. The firm has a market capitalization of $22.00 billion, a P/E ratio of 18.35, a P/E/G ratio of 1.74 and a beta of 0.59. United Therapeutics Corporation has a 52 week low of $302.19 and a 52 week high of $609.35.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating analysts' consensus estimates of $6.86 by $0.41. The company had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The company's revenue for the quarter was down 1.9% on a year-over-year basis. During the same quarter last year, the company earned $6.41 earnings per share. On average, equities analysts forecast that United Therapeutics Corporation will post 26.33 earnings per share for the current year.

About United Therapeutics

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source